Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 5/20 | 0.62 |
| ▸ | ELANE | P08246 | 5/20 | 0.55 |
| ▸ | PLAU | P00749 | 3/20 | 0.55 |
| ▸ | F2 | P00734 | 2/20 | 0.55 |
| ▸ | RORC | P51449 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.42 |
| ▸ | RARG | P13631 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14333217 | 0.87 | SCN9A (0.57) | SCN9AELANEPLAUF2RORC | |
| SCHEMBL717998 | 0.86 | ELANE (0.63) | SCN9AELANEPLAUF2RORC | |
| SCHEMBL16260376 | 0.85 | SCN9A (0.56) | SCN9AELANEPLAUF2RORC | |
| SCHEMBL4790822 | 0.84 | SCN9A (0.55) | SCN9AELANEPLAUF2RORC | |
| SCHEMBL14406104 | 0.83 | SCN9A (0.54) | SCN9AELANEPLAUF2RORC | |
| SCHEMBL6136810 | 0.83 | ALDH1A1 (0.54) | SCN9ARORCALDH1A1HPGDFGFR1 | |
| SCHEMBL14406063 | 0.82 | SCN9A (0.53) | SCN9AELANEPLAUF2RORC | |
| SCHEMBL14333720 | 0.81 | ELANE (0.54) | SCN9AELANEPLAUF2ALDH1A1 | |
| SCHEMBL4791726 | 0.81 | SCN9A (0.55) | SCN9AELANEPLAUF2RORC | |
| SCHEMBL4795077 | 0.80 | SCN9A (0.57) | SCN9AELANEPLAUF2RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060135589-A1 | 1h-Indazole-3-carboxamide compounds as cyclin dependent kinase (cdk) inhibitors | ASTEX TECHNOLOGY, INC. (GB) | 2006-06-22 | — | — | US | disclosed |
| EP-1534685-A1 | 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS CYCLIN DEPENDENT KINASES (CDK) INHIBITORS | Astex Technology Limited (GB) | 2005-06-01 | — | — | EP | disclosed |
| WO-2005014554-A1 | 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS MAPKAP KINASE MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2005-02-17 | — | — | WO | disclosed |
| WO-2004014864-A1 | 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS CYCLIN DEPENDENT KINASES (CDK) INHIBITORS | ASTEX TECHNOLOGY LIMITED (GB) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135589-A1 | 1h-Indazole-3-carboxamide compounds as cyclin dependent kinase (cdk) inhibitors | CCNC, CDK1, CDK7 | SCN9A 1836/4885ELANE 4267/4885PLAU 4377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.